147290-68-4

Upstream product

• 64-04-0 phenethylamine 
• 171049-67-5 tert-butyl-3-(bromomethyl)-4-nitrobenzoate 
• 147290-67-3 tert-butyl 3-methyl-4-nitrobenzoate 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 

Downstream Products

• 147290-69-5 t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate 
• 171049-45-9 [7-(4-{Amino-[(Z)-benzyloxycarbonylimino]-methyl}-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 147290-71-9 2-{4-tert-Butoxycarbonyl-2-[(tert-butoxycarbonyl-phenethyl-amino)-methyl]-phenylamino}-succinic acid dimethyl ester 
• 292135-38-7 [7-(4-Carbamimidoyl-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 171049-34-6 methyl 7-carboxy-3-oxo-1,4-benzodiazepine-2-acetate 
• 147290-70-8 tert-butyl 4-amino-3-[[N-(tert-butoxycarbonyl)-N-phenethylamino]methyl]benzoate 

Relevant academic research and scientific papers

Fab I inhibitors

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment of bacterial infections.

Bicyclic fibrinogen antagonists

PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formula: STR1 wherein A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; R is at least one substituent chosen from the group of R7, or Q--C1-4 alkyl, Q--C2-4 alkenyl, Q--C2-4 alkynyl, preferably substituted by an acidic function; R* is H, Q--C1-6 alkyl, Q--C1-6 oxoalkyl, Q--C2-6 alkenyl or Q--C2-4 alkynyl, C3-6 cycloalkyl, Ar or Het, optionally substituted by one or more substitutents; and R6 is preferably a substituent containing a basic nitrogen moiety; or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.